Literature DB >> 22684300

Polypharmacy in attention deficit hyperactivity disorder treatment: current status, challenges and next steps.

Regina Bussing1, Almut G Winterstein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22684300     DOI： 10.1007/s11920-012-0295-6

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN： 1523-3812            Impact factor:   5.285


× No keyword cloud information.
  23 in total

1.  The dopamine dilemma: using stimulants and antipsychotics concurrently.

Authors:  Jason Yanofski
Journal:  Psychiatry (Edgmont)       Date:  2010-06

2.  ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents.

Authors:  Mark Wolraich; Lawrence Brown; Ronald T Brown; George DuPaul; Marian Earls; Heidi M Feldman; Theodore G Ganiats; Beth Kaplanek; Bruce Meyer; James Perrin; Karen Pierce; Michael Reiff; Martin T Stein; Susanna Visser
Journal:  Pediatrics       Date:  2011-10-16       Impact factor: 7.124

3.  National trends in concomitant psychotropic medication with stimulants in pediatric visits: practice versus knowledge.

Authors:  Vinod Bhatara; Michael Feil; Kimberly Hoagwood; Benedetto Vitiello; Bonnie Zima
Journal:  J Atten Disord       Date:  2004-05       Impact factor: 3.256

4.  Quality of care for childhood attention-deficit/hyperactivity disorder in a managed care medicaid program.

Authors:  Bonnie T Zima; Regina Bussing; Lingqi Tang; Lily Zhang; Susan Ettner; Thomas R Belin; Kenneth B Wells
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2010-10-29       Impact factor: 8.829

5.  Improving psychotherapeutic medication prescribing in Florida: implementation of the Florida Medicaid Drug Therapy Management Program (MDTMP).

Authors:  Robert J Constantine; Marie A McPherson; Mary Elizabeth Jones; Rajiv Tandon; Edmund R Becker
Journal:  Community Ment Health J       Date:  2012-03-01

6.  Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems.

Authors:  Kirsten K Viktil; Hege S Blix; Tron A Moger; Aasmund Reikvam
Journal:  Br J Clin Pharmacol       Date:  2006-08-30       Impact factor: 4.335

Review 7.  Optimising drug treatment for elderly people: the prescribing cascade.

Authors:  P A Rochon; J H Gurwitz
Journal:  BMJ       Date:  1997-10-25

8.  A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic.

Authors:  Margaret Weiss; Constadina Panagiotopoulos; Lauren Giles; Christopher Gibbins; Boris Kuzeljevic; Jana Davidson; Rebecca Harrison
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-10       Impact factor: 2.576

9.  Determinants of initial pharmacological treatment for youths with attention-deficit/hyperactivity disorder.

Authors:  Chih-Ying Chen; Tobias Gerhard; Almut G Winterstein
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-04       Impact factor: 2.576

10.  Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid managed care.

Authors:  Andrés Martin; Thomas Van Hoof; Dorothy Stubbe; Tierney Sherwin; Lawrence Scahill
Journal:  Psychiatr Serv       Date:  2003-01       Impact factor: 3.084
View more
  8 in total

1.  Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression.

Authors:  Kenneth D Gadow; L Eugene Arnold; Brooke S G Molina; Robert L Findling; Oscar G Bukstein; Nicole V Brown; Nora K McNamara; E Victoria Rundberg-Rivera; Xiaobai Li; Heidi L Kipp; Jayne Schneider; Cristan A Farmer; Jennifer L Baker; Joyce Sprafkin; Robert R Rice; Srihari S Bangalore; Eric M Butter; Kristin A Buchan-Page; Elizabeth A Hurt; Adrienne B Austin; Sabrina N Grondhuis; Michael G Aman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2014-06-12       Impact factor: 8.829

2.  Severely Aggressive Children Receiving Stimulant Medication Versus Stimulant and Risperidone: 12-Month Follow-Up of the TOSCA Trial.

Authors:  Kenneth D Gadow; Nicole V Brown; L Eugene Arnold; Kristin A Buchan-Page; Oscar G Bukstein; Eric Butter; Cristan A Farmer; Robert L Findling; David J Kolko; Brooke S G Molina; Robert R Rice; Jayne Schneider; Michael G Aman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2016-04-13       Impact factor: 8.829

3.  Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder.

Authors:  Cristan A Farmer; Nicole V Brown; Kenneth D Gadow; L Eugene Arnold; David G Kolko; Robert L Findling; Brooke S G Molina; Kristin A Buchan-Page; Robert R Rice; Srihari S Bangalore; Oscar Bukstein; E Victoria Rundberg-Rivera; Nora McNamara; Michael G Aman
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-04       Impact factor: 2.576

4.  Combination and switching of stimulants in children and adolescents with attention deficit/hyperactivity disorder in quebec.

Authors:  Leila Ben Amor; Vanja Sikirica; Martin Cloutier; Jean Lachaine; Annie Guerin; Valerie Carter; Paul Hodgkins; Judy van Stralen
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2014-09

5.  Understanding the Diversity of Pharmacotherapeutic Management of ADHD With Co-occurring Autism: An Australian Cross-Sectional Survey.

Authors:  Olivia J Mellahn; Rachael Knott; Jeggan Tiego; Kathryn Kallady; Katrina Williams; Mark A Bellgrove; Beth P Johnson
Journal:  Front Psychiatry       Date:  2022-06-27       Impact factor: 5.435

6.  What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder?

Authors:  Michael G Aman; Oscar G Bukstein; Kenneth D Gadow; L Eugene Arnold; Brooke S G Molina; Nora K McNamara; E Victoria Rundberg-Rivera; Xiaobai Li; Heidi Kipp; Jayne Schneider; Eric M Butter; Jennifer Baker; Joyce Sprafkin; Robert R Rice; Srihari S Bangalore; Cristan A Farmer; Adrienne B Austin; Kristin A Buchan-Page; Nicole V Brown; Elizabeth A Hurt; Sabrina N Grondhuis; Robert L Findling
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2013-11-18       Impact factor: 8.829

7.  Inter-class Concomitant Pharmacotherapy in Medicaid-Insured Youth Receiving Psychiatric Residential Treatment.

Authors:  Gail A Edelsohn; Kemal Eren; Meghna Parthasarathy; Neal D Ryan; Amy Herschell
Journal:  Front Psychiatry       Date:  2021-05-20       Impact factor: 4.157

8.  Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United States.

Authors:  Zhou Zhou; Keith A Betts; Iryna Bocharova; David Kinrich; William M Spalding
Journal:  J Atten Disord       Date:  2018-07-10       Impact factor: 3.256
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.